Tawfic Shereen O, Abdel Halim Dalia M, Albarbary Ameera, Abdelhady Mohamed
Dermatology Department, Cairo University Kasr Alainy Faculty of Medicine, Cairo, Egypt.
Lasers Surg Med. 2019 Jan;51(1):27-33. doi: 10.1002/lsm.23032. Epub 2018 Nov 15.
Melasma continues to be a disease that is difficult to treat with no fully satisfactory results. The role of a fractional CO laser in its treatment is controversial. The addition of tranexamic acid (TXA) might be helpful.
To assess the efficacy of a low-power fractional CO laser alone versus its combination with tranexamic acid used either topically or intradermally for melasma treatment.
A randomized comparative split-face study included a total of thirty female patients with bilateral, symmetrical melasma. The whole face was subjected to treatment via a low-power (12 Watts) fractional ablative CO laser. One side was randomly assigned to topical application of tranexamic acid solution after the session immediately or intradermal microinjection of tranexamic acid prior to the laser session. Sessions were conducted every 4-6 weeks for five consecutive sessions. Assessments were done using the melasma area severity index MASI score, melanin index (MI), and erythema index (EI) before sessions and 2 weeks after the final session.
After treatment, there was significant reduction in the MASI score on both sides of the face; the side treated with the fractional CO2 laser alone and the side treated with fractional CO laser combined with TXA (topically or intradermal injection) (P-values 0.007, <0.001, and 0.016, respectively). MI was significantly lower on the side receiving fractional CO laser alone and the side receiving fractional CO laser combined with intradermal injection of TXA (P-values <0.001 and 0.003, respectively), while the EI showed significant improvement only on the side receiving fractional CO laser alone (P-value = 0.023). Although patients reported no differences in improvement on either treated side, the degree of improvement regarding the MASI score was better on the side receiving fractional CO laser alone. Regarding MI, the degree of improvement was higher on the side receiving fractional CO laser combined with intradermal injection of TXA than on the side receiving fractional CO laser alone; however, this improvement did not reach statistical significance. Minimal complications occurred in the form of mild pain.
A low-power fractional CO laser is an effective, safe treatment for melasma. However, the addition of tranexamic acid (either topically or intradermally) to a fractional CO laser should be further studied. Lasers Surg. Med. 51:27-33, 2019. © 2018 Wiley Periodicals, Inc.
黄褐斑仍然是一种难以治疗且无法取得完全满意效果的疾病。剥脱性二氧化碳(CO)点阵激光在其治疗中的作用存在争议。添加氨甲环酸(TXA)可能会有所帮助。
评估低能量剥脱性二氧化碳点阵激光单独使用,以及联合外用或皮内注射氨甲环酸治疗黄褐斑的疗效。
一项随机对照半脸研究共纳入30例双侧对称性黄褐斑女性患者。全脸接受低能量(12瓦)剥脱性二氧化碳点阵激光治疗。一侧在每次治疗后立即随机分配外用氨甲环酸溶液,另一侧在激光治疗前皮内微量注射氨甲环酸。每4 - 6周进行一次治疗,连续治疗5次。在每次治疗前及最后一次治疗后2周,使用黄褐斑面积和严重程度指数(MASI)评分、黑色素指数(MI)和红斑指数(EI)进行评估。
治疗后,两侧面部的MASI评分均显著降低;单独使用剥脱性二氧化碳点阵激光治疗的一侧以及联合外用或皮内注射氨甲环酸使用剥脱性二氧化碳点阵激光治疗的一侧(P值分别为0.007、<0.001和0.016)。单独使用剥脱性二氧化碳点阵激光治疗的一侧以及联合皮内注射氨甲环酸使用剥脱性二氧化碳点阵激光治疗的一侧MI显著更低(P值分别为<0.001和0.003),而EI仅在单独使用剥脱性二氧化碳点阵激光治疗的一侧有显著改善(P值 = 0.023)。尽管患者报告两侧治疗后的改善情况无差异,但单独使用剥脱性二氧化碳点阵激光治疗的一侧在MASI评分方面的改善程度更好。关于MI,联合皮内注射氨甲环酸使用剥脱性二氧化碳点阵激光治疗的一侧改善程度高于单独使用剥脱性二氧化碳点阵激光治疗的一侧;然而,这种改善未达到统计学意义。出现的并发症极少,表现为轻度疼痛。
低能量剥脱性二氧化碳点阵激光是一种治疗黄褐斑有效且安全的方法。然而,在剥脱性二氧化碳点阵激光治疗中添加氨甲环酸(外用或皮内注射)仍需进一步研究。《激光外科与医学》51:27 - 33, 2019。© 2018威利期刊公司